CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor outcomes with current therapies. Gemcitabine is the primary adjuvant drug used clinically, but its effectiveness is limited. In this study, our objective was to utilize a rationale-driven approach to identify novel biomarkers...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Colbert, Lauren E., Petrova, Aleksandra V., Fisher, Sarah B., Pantazides, Brooke G., Madden, Matthew Z., Hardy, Claire W., Warren, Matthew D., Pan, Yunfeng, Nagaraju, Ganji P., Liu, Elaine A., Saka, Burcu, Hall, William A., Shelton, Joseph W., Gandhi, Khanjan, Pauly, Rini, Kowalski, Jeanne, Kooby, David A., El-Rayes, Bassel F., Staley, Charles A., Adsay, N. Volkan, Curran, Walter J., Landry, Jerome C., Maithel, Shishir K., Yu, David S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4025946/
https://ncbi.nlm.nih.gov/pubmed/24626090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1996
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados